Skip to content
The Policy VaultThe Policy Vault

Afinitor — CareFirst (Caremark)

well differentiated Grade 3 neuroendocrine tumors

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months